Abstract There is a need for noninvasive biomarkers that can identify patients with progressive liver fibrosis and monitor response to antifibrotic therapy. An equally important need is identification of patients with spontaneous fibrosis regression, since they may not need treatment nor be included in clinical studies with fibrosis as end point. Circulating biomarkers, originating from […]
Assessment of liver fibrosis progression and regression by a serological collagen turnover profile.
January 1, 2019
Am J Physiol Gastrointest Liver Physiol